

US Patent Issued for CanBas's CBP501



Numazu-city, Shizuoka, Japan - February 22, 2006 -- CanBas Co., Ltd., a privately held drug discovery company located in Numazu-city, Shizuoka, Japan, announced today that a patent for CanBas's CBP501 has been issued by the US Patent and Trademark Office. (US Patent #6,995,135)

About CanBas

CanBas was spun off of the research of three scientists from the Nagoya City Medical School and Fujita Health Medical School. These scientists founded CanBas as a drug development biotech with help by Angels and Venture Capitalists in 2000.

CanBas's core technologies include drugs that target the G2 checkpoint and a screening system to find selective blockers of the G2 checkpoint.

The company's leading compound CBP501 is currently under investigation in Phase I clinical trial in the United States.

For more information about CanBas, please visit www.canbas.co.jp.

Company Contact

Masashi Suganuma, M.D., Ph.D.

Executive Vice President & COO

Phone: +81-55-954-3666

Fax: +81-55-954-3668

or >> [Contact form](#)